Elicio Therapeutics: Funding, Investors & Team (Oct 2026)
Elicio is dedicated to re-engineering the body's immunological response to cancer in order to improve the lives of patients and their families. Elicio is developing effective vaccines and immunotherapies for a variety of aggressive tumors by merging his knowledge in immunology and materials science. The Elicio Amphiphile platform allows for accurate targeting and delivery of immunogens directly to the lymphatic system, the "brain center" of the immune response, in order to greatly amplify and strengthen the body's natural system of defenses, destroy cancer, and prevent its recurrence. This significantly improved anti-tumor efficacy and long-term protective memory may enable the human immune system to perform to its maximum capacity in the fight against cancer. Initial patient studies for Elicio's main Amphiphile vaccines against head and neck, colorectal, and pancreatic cancer will start in early 2020.
Elicio Therapeutics has raised $203M across 6 funding rounds on record, the most recent an undisclosed round of $100M announced in Mar 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Elicio Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Elicio Therapeutics Funding Rounds
Elicio Therapeutics raised $73.0M in a Series B announced in Feb 2021.
9 months later, a Debt Financing of $14.5M was announced in Nov 2021.
10 months later, a Grant of $2.8M was announced in Sep 2022.
2 months later, an undisclosed round of $2.8M was announced in Nov 2022.
2 months later, an undisclosed round of $10.0M was announced in Jan 2023.
3.2 years later, an undisclosed round of $100M was announced in Mar 2026.
Elicio Therapeutics Founders and Leadership Team
Contact details for the Elicio Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Elicio Therapeutics Funding Compared to Other Biotechnology Startups
Elicio Therapeutics' latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Elicio Therapeutics in Biotechnology and Cambridge
Companies Similar to Elicio Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Elicio Therapeutics Funding FAQs
What does Elicio Therapeutics do?
Elicio is dedicated to re-engineering the body's immunological response to cancer in order to improve the lives of patients and their families. Elicio is developing effective vaccines and immunotherapies for a variety of aggressive tumors by merging his knowledge in immunology and materials science. The Elicio Amphiphile platform allows for accurate targeting and delivery of immunogens directly to the lymphatic system, the "brain center" of the immune response, in order to greatly amplify and strengthen the body's natural system of defenses, destroy cancer, and prevent its recurrence. This significantly improved anti-tumor efficacy and long-term protective memory may enable the human immune system to perform to its maximum capacity in the fight against cancer. Initial patient studies for Elicio's main Amphiphile vaccines against head and neck, colorectal, and pancreatic cancer will start in early 2020.
How much funding has Elicio Therapeutics raised?
Elicio Therapeutics has raised $203M across 6 rounds on record. The most recent is an undisclosed round of $100M announced in Mar 2026.
When did Elicio Therapeutics last raise funding?
Elicio Therapeutics' most recent funding round on record is an undisclosed round of $100M, announced in Mar 2026.
Who is the CEO of Elicio Therapeutics?
Robert Connelly is listed as CEO at Elicio Therapeutics.
Where is Elicio Therapeutics headquartered?
Elicio Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Elicio Therapeutics have?
Elicio Therapeutics is in the 11-50 employee band.
How does Elicio Therapeutics' funding compare to other Biotechnology startups?
Elicio Therapeutics' latest round of $100M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Elicio Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Elicio Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.